DeepMed Research

Jacobio Pharmaceuticals Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: JAB 21822

First Posted Date: 2022-03-11

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 104

Registration Number: NCT05276726

Locations: 🇨🇳
Research site019, Hangzhou, Zhejiang, China
🇨🇳
Research site02, Beijing, Beijing, China
🇨🇳
Research site011, Shenzhen, Guangdong, China

and more 18 locations

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Phase 1

Active, not recruiting

Conditions: Advanced Colorectal Cancer
Appendiceal Cancer
Small Intestinal Cancer

Interventions: Drug: JAB-21822
Drug: Cetuximab

First Posted Date: 2022-01-18

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT05194995

Locations: 🇨🇳
Research site31, Beijing, Beijing, China
🇨🇳
Research site01, Beijing, Beijing, China
🇨🇳
Research site02, Beijing, Beijing, China

and more 14 locations

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Biological: JAB-BX102 (anti-CD73 monoclonal antibody)
Biological: pembrolizumab (anti-PD-1 monoclonal antibody)

First Posted Date: 2022-01-03

Last Posted Date: 2024-03-22

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 62

Registration Number: NCT05174585

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

and more 3 locations

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Phase 1

Active, not recruiting

Conditions: NSCLC
Solid Tumor

Interventions: Drug: JAB-21822

First Posted Date: 2021-08-17

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 311

Registration Number: NCT05009329

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
NSCLC
CRC

Interventions: Drug: JAB-21822 (KRAS G12C inhibitor)
Drug: Cetuximab (EGFR inhibitor)

First Posted Date: 2021-08-12

Last Posted Date: 2023-09-07

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT05002270

Locations: 🇺🇸
Mayo Clinc, Jacksonville, Florida, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Phase 1

Conditions: Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Advanced Solid Tumor
Esophageal Squamous Cell Carcinoma

Interventions: Drug: JAB-3068
Drug: PD1 inhibitor

First Posted Date: 2021-01-22

Last Posted Date: 2021-07-28

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 118

Registration Number: NCT04721223

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
NSCLC

Interventions: Drug: JAB-3312
Drug: Binimetinib
Drug: Pembrolizumab
Drug: Sotorasib
Drug: Osimertinib

First Posted Date: 2021-01-22

Last Posted Date: 2025-04-11

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 58

Registration Number: NCT04720976

Locations: 🇺🇸
Research Site, Salt Lake City, Utah, United States

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Phase 1

Recruiting

Conditions: AML
MF
NSCLC
SCLC
CRPC
ESCC
Ovarian Carcinoma
Malignant Tumor

Interventions: Drug: JAB-8263

First Posted Date: 2020-12-29

Last Posted Date: 2023-03-10

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 152

Registration Number: NCT04686682

Locations: 🇨🇳
Tianjin, Tianjin, Tianjin, China

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

Phase 1

Conditions: Solid Tumors, Adult

Interventions: Drug: JAB-8263

First Posted Date: 2020-10-14

Last Posted Date: 2022-03-14

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT04587479

Locations: 🇺🇸
Florida Cancer Center, Lake Mary, Lake City, Florida, United States
🇺🇸
SCRI HeatlthONE, Denver, Colorado, United States
🇺🇸
Tennessee Oncology Nashville, Nashville, Tennessee, United States

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Phase 1

Completed

Conditions: Colorectal Cancer
Non-small Cell Lung Cancer
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Breast Cancer
Other Solid Tumors
Pancreatic Ductal Carcinoma

Interventions: Drug: JAB-3312

First Posted Date: 2019-10-09

Last Posted Date: 2025-05-20

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 17

Registration Number: NCT04121286

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical Collage Hospital, Beijing, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy